AHP To Cut Jobs At Cyanamid
American Home Products is cutting 300 jobs at the recently-acquired American Cyanamid unit, effective January 31, 1995. Around 66% of this number will go from the former headquarters of the acquired company in Wayne, where 1,800 staff are employed. AHP says that there will also be cuts in Washington DC, the Davis & Geck facility in Connecticut, and several other locations.
Cyanamid's chief executive and president, Albert Costello and Frank Atlee, will leave the company at the time the job cuts come into effect. AHP's says that further plans will be announced early next year. Mr Costello sent a letter to Cyanamid staff in November, the tone of which indicated that AHP would move swiftly to integrate the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze